Rovida Advisors’s GoodRx Holdings GDRX Stock Holding History

Rovida Advisors’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-91,300	Closed	-$3.56M	–	50
2021 Q1	$3.56M	Buy	+91,300	New	+$4.11M	0.17%	40

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Atreides Management Boston, Massachusetts $5B AUM 78.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Rovida Advisors's GDRX Position: Q2 2021 in Review

Rovida Advisors sold out of GoodRx Holdings (GDRX) in Q2 2021, closing a stake of 91,300 shares — an estimated $3.56M sold.

Rovida Advisors first reported a position in GDRX in Q1 2021 and held it in 1 quarter. The position peaked at $3.56M in Q1 2021. 199 funds tracked by Wall St. Rank hold GDRX as of Q2 2021.

Rovida Advisors reported no remaining GoodRx Holdings position as of Q2 2021 after selling out during the quarter.
Rovida Advisors sold 91,300 GoodRx Holdings shares in Q2 2021, an estimated $3.56M.
Rovida Advisors first reported a position in GoodRx Holdings in Q1 2021 and held it in 1 quarter.
Rovida Advisors's GoodRx Holdings position peaked at $3.56M in Q1 2021.
199 funds tracked by Wall St. Rank held GoodRx Holdings as of Q2 2021.

Based on Rovida Advisors's 13F filing for Q2 2021, filed 10 Aug 2021.